Archived Monthly Oncology Tumor Boards: Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix

The management of cervical cancer specific to histology, stage, and setting has changed tremendously, and a review of new/latest data is important and helpful for the practitioners in treatment decision-making. As immunotherapies are revolutionizing the treatment landscape, the systemic therapy section of the NCCN Guidelines® for Cervical Cancer has drastically evolved over the past few years to reflect new approvals and indications. Knowledge of this topic will guide the practitioners in appropriately prioritizing these new treatment options to further improve patient outcomes. The management of different histotypes of cervical cancer is also changing with emerging treatment options. The NCCN Guidelines for Cervical Cancer include distinct treatment guidelines for neuroendocrine carcinoma of the cervix, a rare type of cervical cancer. Clinicians can benefit from continued education on comparing treatment options to best manage different histological types of cervical cancer.

Target Audience

This activity is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Review the relevant practice changing results from recent clinical studies for cervical cancer.
  • Describe approaches for treatment decision-making for patients with stage IV/metastatic or recurrent cervical cancer and how to strategize systemic treatment options as first- and second-line therapies.
  • Discuss the NCCN recommended treatment options for small cell neuroendocrine carcinoma of the cervix.
Additional information

This activity is supported by educational grants from AstraZeneca, GSK, Lantheus, and Novartis. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
Course expires: 

Nadeem R. Abu-Rustum, MD
Memorial Sloan Kettering Cancer Center

Claire F. Friedman, MD
Memorial Sloan Kettering Cancer Center

Latasha Anderson-Dunkley, MSN, ANP-BC
Memorial Sloan Kettering Cancer Center


NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no financial relationships with ineligible companies to disclose.

Latasha Anderson-Dunkley, MSN, ANP-BC

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Nadeem R. Abu-Rustum, MD
GRAIL: Grant/Research Support

Claire F. Friedman, MD
Aadi Bioscience: Consulting Fee
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Daiichi-Sankyo Co.: Grant/Research Support
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Hotspot: Grant/Research Support
Marengo: Grant/Research Support
Merck & Co., Inc. Grant/Research Support; Scientific Advisor
Mersana: Grant/Research Support
Puma Biotechnology: Honoraria

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-131-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 5, 2024. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00057347; Approval #: 230003795

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing